-
Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan
•
Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based Cytokinetics, Incorporated (NASDAQ: CYTK), acquiring exclusive development and commercialization rights to aficamten in Japan. The agreement is subject to certain reserved development rights of Cytokinetics. Phase III Study and Global Trial ExpansionUnder the terms of…
-
Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
•
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from the European Commission (EC) for its biosimilar of Bayer/Regeneron’s (ETR: BAYN / NASDAQ: REGN) Eylea (aflibercept). The product is now available in the form of a 2 mg vial kit and pre-filled syringe for intravitreal…
-
Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals
•
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6% year-on-year (YOY) growth in constant currency terms to EUR 9.968 billion (USD 10.59 billion) in global group sales. This growth was driven by strong performances in the Pharmaceuticals and Consumer Healthcare segments, offsetting a decline…
-
Bayer AG Receives FDA 510(k) Clearance for MEDRAD Centargo CT Injection System
•
Germany-based Bayer AG (ETR: BAYN) has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MEDRAD Centargo CT Injection System. This innovative multi-patient injector is designed to enhance workflow efficiency and integrates seamlessly with Bayer’s existing portfolio of products, particularly in high-volume…
-
AskBio’s AB-1003 Receives Rare Pediatric Disease and Orphan Drug Designations from FDA
•
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG (ETR: BAYN), has announced that it has received both rare pediatric disease designation (RPDD) and orphan-drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational gene therapy, AB-1003 (LION-101). The therapy targets limb-girdle muscular dystrophy…
-
Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement
•
Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the “Salesforce on Alibaba Cloud” solution, creating an all-new customer interaction platform, OPERA 2.0, for thousands of internal Bayer users. Bayer is one of the first multinational pharmaceutical companies in China to implement a new customer…
-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives
•
German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the China Population Welfare Foundation (CPWF) at the 7th China International Import Expo (CIIE). The collaboration aims to enhance public health awareness by promoting health science popularization and advocacy activities. Joint Focus on Health Initiatives Under…
-
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
•
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the launch of the China Center of Innovation and Partnership (CIIP) at the SH-INNO incubator in Shanghai. The incubator, established in August this year, is a collaborative effort between Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607),…
-
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced last week the opening of a new life sciences incubator in Shanghai, named Bayer Co.Lab Shanghai. The incubator is located in the Shanghai Innovation (SH-INNO) Park within the Zhanghiang biopharma cluster and is part of…
-
Bayer’s Finerenone Shows Promise in Heart Failure Treatment, Outperforms Placebo in Phase III Trial
•
FRANKFURT—Bayer AG (FRA: BAYN) has announced positive results from the Phase III FINEARTS-HF study for its mineralocorticoid receptor (MR) antagonist, finerenone. Originally approved for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes, finerenone is now being developed for heart failure, a condition with significant market potential.…
-
Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare
•
Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has reported its financial results for the second quarter of 2024. The company posted a 3.1% year-on-year (YOY) increase in constant currency terms, reaching EUR 11.1 billion (USD 12.12 billion) in global group sales for the…
-
Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors
•
Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its Category 1 drug BAY 3375968. This novel Fc optimized anti-CCR8 antibody is currently the subject of a Phase I clinical study globally. BAY 3375968 has…
-
Bayer Restructures China Business into Five Sectors and Six Departments
•
Bayer (ETR: BAYN), the German pharmaceutical and life sciences giant, has announced a strategic restructuring of its China business, carving it into five distinct business sectors and six functional departments. This reorganization is aimed at enhancing operational efficiency and strategic focus within the dynamic Chinese market. The five business sectors…
-
Bayer’s HER2 Targeting Drug BAY 2927088 Earns Breakthrough Designation in China
•
The Center for Drug Evaluation (CDE) in China has granted Breakthrough Therapy Designation (BTD) to German pharmaceutical giant Bayer (ETR: BAYN)’s drug candidate BAY 2927088 for the treatment of HER2 mutant non-small cell lung cancer (NSCLC), as indicated on the CDE’s official website. This marks a significant regulatory milestone for…
-
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
•
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in the field of tumor companion diagnostics (CDx), this time with the German multinational corporation, Bayer. Previously Burning Rock had collaborated with Germany-based Merck KGaA in late 2021 for the development of CDx to support Merck’s…
-
Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China
•
Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in Jiangsu province to establish a new supply center. The German multinational pharmaceutical company will invest RMB 600 million (USD 83 million) in the initial phase of the project, with the facility expected to become operational…
-
Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC
•
Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced an early-stage trial for its targeted radionuclide therapy, 225Ac-PSMA-Trillium. The trial is focused on treating advanced metastatic castration-resistant prostate cancer (mCRPC). This innovative therapeutic candidate incorporates a PSMA-targeting small molecule designed to deliver an alpha…
-
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024, showing a slight 0.6% year-on-year (YOY) decrease in group sales to EUR 13.8 billion (USD 14.9 billion), excluding portfolio and exchange rate effects. The pharmaceuticals business segment reported a 3.9% increase in sales, reaching EUR…
-
Bayer CEO Joins German Chancellor on China Visit, Announces New Investments
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company based in Germany, recently had its CEO, Bill Anderson, accompany German Chancellor Olaf Scholz on a high-profile visit to China. In a brief interview with Xinhua, Anderson emphasized Bayer’s dedication to developing innovative drugs and…
-
Bayer Partners with Hologic to Develop Contrast-Enhanced Mammography Solution for Breast Cancer Diagnosis
•
Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced a strategic partnership with Hologic (NASDAQ: HOLX), a leading women’s health specialist. The collaboration aims to develop a contrast-enhanced mammography (CEM) solution that serves as a cost-effective adjunct to traditional mammography for breast cancer diagnosis.…
-
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will result in the layoff of up to 680 staff members across its Swiss and US development teams. This move, reported by Endpoints News, comes on the heels of similar announcements from industry peers Bayer (ETR:…
-
Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions
•
Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology company Google Cloud (NASDAQ: GOOG) to develop artificial intelligence (AI) driven medical imaging solutions focused on radiology. This strategic collaboration aims to leverage patient data sets to create tools that alleviate the burden of repetitive…
-
Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101
•
Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has achieved a significant milestone with the completion of a Phase III clinical study for its proprietary ophthalmology product BA9101. This biosimilar version of Bayer’s Eylea (aflibercept) targets the treatment of recurrent or metastatic esophageal squamous…
-
Roche Invests EUR 90 Million in New Gene Therapy Center in Germany
•
Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in Germany, following an investment of EUR 90 million (USD 97.4 million). The expansive 2,500 square meter facility is designed to specialize in the production of gene vectors for clinical trials across various therapeutic areas, including…
-
Bayer Eliminates C-Level Roles in Restructuring Efforts to Boost Profitability
•
Germany’s Bayer (ETR: BAYN) has taken significant steps in its restructuring efforts by eliminating 8 out of 14 C-level positions, including key roles such as the head of global marketing, head of radiology, and president of the consumer health division. This move is part of the company’s strategy to simplify…
-
Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology
•
Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader Thermo Fisher Scientific (NYSE: TMO) to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) aimed at enhancing precision cancer therapies. Financial terms of the collaboration remain undisclosed. According to the press release, the diagnostic tests…
-
Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial
•
Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled late-stage trial of its NK-1,3 receptor antagonist, elinzanetant. The trial successfully met its primary endpoint, demonstrating a significant reduction in the frequency of moderate-to-severe vasomotor symptoms (VMS) associated with menopause by week 12. The 52-week…
-
Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates
•
Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of declining sales that culminated in a 1.2% year-on-year (YOY) drop in constant currency and portfolio-adjusted terms, reaching €47.6 billion (USD 51.7 billion). The Pharmaceuticals segment generated €18.1 billion (USD 19.6 billion) with a 0.4% decline…
-
Bayer’s BAY 2927088 Receives FDA Breakthrough Therapy Designation for HER2-Mutated NSCLC
•
The US Food and Drug Administration (FDA) has granted Germany-based Bayer AG (ETR: BAYN) breakthrough therapy designation for its tyrosine kinase inhibitor (TKI) BAY 2927088. The drug is under review as a potential treatment for unresectable or metastatic non-small cell lung cancer (NSCLC) with activating HER2 (ERBB2) mutations that have…
-
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
•
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic firm Yabao Pharmaceutical Group Co., Ltd. (SHA: 600351) to distribute a generic version of Bayer (ETR: BAYN)’s Nexavar (sorafenib). Under this agreement, Kexing will serve as the exclusive agent for the tyrosine kinase inhibitor (TKI)…
-
Bayer Advances BAY3018250 into Phase II Trial Following Successful Phase I Completion
•
Germany’s Bayer (ETR: BAYN) has launched a double-blind, placebo-controlled mid-stage trial for its potential first-in-class anti-alpha2 antiplasmin (anti-α2ap) drug, BAY3018250, aimed at treating symptomatic proximal deep vein thrombosis (DVT). This advancement comes on the heels of a successful Phase I study. The investigational antibody works by modulating the breakdown of…
-
Bayer Partners with TetraScience to Enhance Data Management in Product Development
•
Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect and process cloud-based scientific data, facilitating enhanced insights for its researchers in product development across various sectors, including cell and gene therapy, biopharma, and crop sciences. This collaboration is a key component of Bayer’s digital…
-
Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges
•
Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model aimed at enhancing its performance and returning to profitable growth. The plan includes significant job cuts as part of an ongoing staff reduction program, with compulsory redundancies set to begin in 2027. In contrast to…
-
Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure
•
Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase II clinical trial of its adeno-associated virus (AAV) therapy AB-1002 targeting congestive heart failure (CHF). This placebo-controlled study aims to assess the safety and efficacy of intracoronary infusion in 90 to 150 adults with non-ischemic…
-
Bayer AG Leads Series D Investment in Jixing Pharmaceuticals, Eyeing Commercialization Rights
•
Bayer AG (ETR: BAYN, OTCMKTS: BAYRY), a leading German pharmaceutical company, has announced a long-term collaboration with Jixing Pharmaceuticals, a China-based firm, following its leadership in a Series D financing round. The investment is being made in conjunction with RTW Investments, the fund that established and supported Jixing. Bayer’s venture…
-
Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response
•
German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health to delve into the study of treatment response and resistance in metastatic hormone-sensitive prostate cancer. The collaborative project will leverage ClearNote’s epigenomic platform, which employs machine learning algorithms to analyze patient blood samples, monitor DNA-based…
-
Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging
•
Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT firm Salus Optima to provide precision health solutions that promote healthy aging through data-driven lifestyle recommendations on mobile devices. This collaboration will leverage Bayer’s extensive global network to distribute Salus Optima’s AI-powered lifestyle analysis technology.…
-
Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System
•
Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical to develop a user-friendly inserter designed for the delivery of Bayer’s hormonal intrauterine systems (IUSs) via the cervix. This collaboration seeks to enhance CrossBay’s CrossGlide inserter, transforming it into a single-handed device aimed at minimizing…
-
Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce
•
Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s saliva-based Chronomics biological age tests through electronic channels. Based in the UK, Hurdle specializes in diagnostics, and its at-home biomarker tests utilize epigenetic markers to measure biological age, positioning them as precision health solutions aimed…
-
Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure
•
German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance of USD 5.75 billion in bonds shortly before disclosing a significant setback in its late-stage pipeline. The company issued the 3 to 30-year maturity bonds on November 16, and then announced the early termination of…
-
Bayer Invests USD 130 Million in Parenteral Drugs Manufacturing Site in Germany
•
Bayer (ETR: BAYN) has inaugurated a new state-of-the-art parenteral drugs manufacturing site at its German headquarters, as part of a comprehensive USD 1 billion program aimed at bolstering the company’s production and innovation capabilities. The new facility, with an investment of USD 130 million, will handle formulation, filling, and lyophilization…
-
Bayer Halts Late-Stage Trial for Asundexian After Underperformance
•
Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate asundexian. Asundexian, once considered a potential blockbuster, was outperformed by the standard of care in preventing stroke and systemic embolism in patients with atrial fibrillation, the most lucrative indication for the drug, with an estimated…
-
Bayer Withdraws Aliqopa FDA Filing Following Missed Phase III Endpoint
•
Germany-based pharmaceutical major Bayer (ETR: BAYN) has announced its decision to withdraw the filing for the kinase inhibitor Aliqopa (copanlisib) with the US Food and Drug Administration (FDA). Aliqopa, which received accelerated approval in 2017 for the treatment of relapsed follicular lymphoma (FL), failed to meet the primary endpoint of…
-
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
•
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration with US biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX). The partnership, which was initially focused on fibrosis, will now shift its attention to precision oncology. This strategic move will see the initiation of up to seven…
-
Bayer Secures Multiple Procurement Deals at the 6th CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced a series of procurement agreements with several Class 3A hospitals in China. Among these institutions is the prestigious Fourth Affiliated Hospital of China Medical University. Bayer’s Commitment to Healthcare Partnerships in ChinaThe agreements signed during…
-
ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions
•
Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550), focusing on the digestive enzyme field. The collaboration aims to explore and promote product development in the digestive tract health sector, with no financial details disclosed. Focus on Digestive Tract Health and…
-
Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth
•
Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023, revealing global sales of EUR 35.8 billion (USD 38.3 billion) between Q1 and Q3, marking a 3.2% year-on-year (YOY) decline. Despite this, the company confirmed its 2023 guidance of EUR 48.5 billion to EUR 49.5…
-
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
•
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a partnership with Shanghai Pharmaceuticals, a leading China-based pharmaceutical distribution giant (SPH; HKG: 2607; SHA: 601607), to co-construct a new life sciences incubator named Co.Lab. This collaboration is designed to foster cutting-edge innovation in cell and…
-
Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management
•
Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing on the clinical characteristics and treatment patterns associated with its mineralocorticoid receptor antagonist (MRA), Kerendia (finerenone). This medication has received global approvals aimed at reducing cardiorenal risk in patients suffering from chronic kidney disease (CKD)…
-
Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies
•
Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the US-based research center, the Broad Institute, until 2028. The partnership focuses on identifying new drug targets in oncology and developing innovative cancer therapies. The financial details of the extended agreement have not been disclosed. Combining…
-
Bayer HealthCare Launches First Innovation Center in Beijing’s ETown
•
Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated within the Beijing Economic-Technological Development Area, commonly referred to as Beijing ETown. This marks a significant expansion of the company’s global footprint and commitment to innovation in the Asia-Pacific region. Collaboration and Research FocusThe German…
-
Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications
•
Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision Diagnostics to jointly develop gadoquatrane, a late-stage contrast agent candidate. This collaboration focuses on advancing three Phase III studies aimed at evaluating the pharmacokinetics, safety, and efficacy of this gadolinium-based molecule in both adults and…
-
Bayer AG Plans Continued Investment in China Amidst Global Challenges
•
Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as stated by Matthias Berninger, Executive Vice-President of Public Affairs, Science, Sustainability, and HSE at Bayer. Berninger’s comments came in an interview with China Daily in anticipation of the China International Import Expo, scheduled for November…
-
Bayer Opens First Cell Therapy Production Facility in the U.S. to Advance Research
•
Bayer AG (ETR: BAYN) has inaugurated its first production site dedicated to cell therapies, marking a significant step in the company’s commitment to advancing research in this innovative field. The new facility, spanning 9,290 square meters, represents a substantial investment of $250 million and enhances Bayer’s biotechnology network, which includes…
-
Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas
•
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery specialist Twist Bioscience (NASDAQ: TWST) to develop antibodies targeting undisclosed disease areas. This collaboration is set to enhance Bayer’s capabilities in antibody discovery and development. Financial Terms of the Collaboration Under the terms of the…
-
China’s NHC Expands Rare Disease List, Includes 21 Cancer Types
•
The National Health Commission (NHC) of China has released an updated national list of rare diseases, doubling the number of conditions to 86, including 21 cancer types. This marks the first update to China’s orphan disease schedule since the initial list of 121 conditions was introduced in 2018. Market Access…
-
Bayer Initiates US Recall of TRK Inhibitor Vitrakvi Due to Mold Contamination
•
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) in the US market following the detection of contamination by the Penicillium brevicompactum mold in the oral solution. While no adverse events have been reported, Bayer has advised…
